IL21 and infection: Starting from day 14 post-infection (p.i.), six animals were treated with five weekly doses of 50 μg/kg IL-21 (s.c.), which represents a dosage similar or lower to those tested in phase I and II clinical trials in humans (IL-21-treated group; orange in graphs) [49].